<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39766">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02588716</url>
  </required_header>
  <id_info>
    <org_study_id>Terlipressin</org_study_id>
    <nct_id>NCT02588716</nct_id>
  </id_info>
  <brief_title>Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.</brief_title>
  <official_title>Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of Terlipressin infusion on blood loss &amp; transfusion requirements in
      cirrhotic patients undergoing major liver resections.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood loss</measure>
    <time_frame>intraoperative period</time_frame>
    <description>blood loss in ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood units transfused</measure>
    <time_frame>intraoperative period</time_frame>
    <description>number of packed RBCs units transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactate level</measure>
    <time_frame>at start and end of resection</time_frame>
    <description>lactate level in blood gas sample in mmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hepatectomy, Surgical Blood Loss, Terlipressin</condition>
  <arm_group>
    <arm_group_label>Terlipressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terlipressin given as intravenous injections of 1mg iv in 50ml of NaCl over 30 mins, then 2mg in 50ml of NaCl infusion (8ml/h), throughout the operation then gradually withdrawn over 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50ml of normal saline over 30 mins, then 50ml of NaCl infusion (8ml/h), throughout the operation then gradually withdrawn over 4 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Terlipressin given as intravenous injections of 1mg iv in 50ml of NaCl over 30 mins, then 2mg in 50ml of NaCl infusion (8ml/h), throughout the operation then gradually withdrawn over 4 hours.</description>
    <arm_group_label>Terlipressin</arm_group_label>
    <other_name>glipressin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>50ml of normal saline over 30 mins, then 50ml of normal saline infusion (8ml/h), throughout the operation then gradually withdrawn over 4 hours.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - portal hypertension

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut University hospital</name>
      <address>
        <city>Assiut</city>
        <state>Asyut Governorate</state>
        <zip>11111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 11, 2016</lastchanged_date>
  <firstreceived_date>October 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mostafa Samy Abbas</investigator_full_name>
    <investigator_title>Lecturer, of Anesthesia &amp; ICU, Assiut University</investigator_title>
  </responsible_party>
  <keyword>Hepatectomy, Surgical Blood Loss, terlipressin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
